



About LUNGevity Foundation (www.LUNGevity.org)

LUNGevity is the nation's leading lung cancer organization investigating lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity's goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.

LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity's comprehensive resources include a medically vetted website, the toll-free HELPLine in partnership with CancerCare®, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our online Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.

Our vision is a world where no one dies of lung cancer.

Funding Research into Earlier Diagnosis and More Effective Treatment

Since 2002, LUNGevity-funded scientific research projects have totaled more than \$20 million. This represents an investment in 127 projects at 59 institutions in 23 states for the most promising lung cancer research proposals in the areas of early detection and targeted therapeutics.

The Foundation funds lung cancer research through a peer-reviewed grant process. Its world-class Scientific Advisory Board meets annually to discuss research strategy, share new scientific developments, oversee ongoing funded projects, review grant proposals, and determine funding of new grants. LUNGevity funds research into both the early detection of lung cancer and treatments that increase survivorship. The LUNGevity Career Development Awards recognize outstanding scientists early in their careers, encouraging their continued development toward leadership in the field by supporting their innovative research projects and providing professional opportunities such as science communications training.

In 2017, LUNGevity initiated a new collaboration by Stand Up To Cancer, LUNGevity, and the American Lung Association's LUNG Force to create and fund the first-ever Lung Cancer Interception Dream Team. This innovative, multi-year award, if successful, will enable doctors to find lung cancer early and intercept it when it is most treatable.

Translating the Patient Voice into Action

LUNGevity launched its Patient-Focused Research Center (Patient FoRCe) in 2017 as a new bridge to connect the patient voice with healthcare professionals, regulators, policymakers, and developers of drugs to ensure that their voices are heard and incorporated into decisions. Patient FoRCe is changing the paradigm in lung cancer from assumptions being made about patient preferences to evidence-based conclusions about what patients value.

Support, Education, and Advocacy Resources

As a thought leader and community hub, LUNGevity also provides many resources directly to the lung cancer community, including the Lung Cancer Support Community (LCSC), the largest dedicated social network offering support to anyone touched by lung cancer. Created in 2002, LCSC provides users with an extensive message board for peer-to-peer support. Other resources include LifeLine and Clinical Trial Ambassadors, both telephone/email buddy programs; a blog by survivors and caregivers; the Experts blog, providing medically vetted information on the latest advances in lung cancer research and treatment; a clinical trial finder; and tools for those interested in becoming advocates.

LUNGevity added new patient tools in 2017 to help patients navigate their lung cancer diagnosis. The Lung Cancer HELPLine offers toll-free, personalized support for patients and caregivers. Oncology social workers are available to help manage emotional, financial, and support challenges. The Lung Cancer Navigator is a customizable mobile app that helps patients understand their diagnosis and provides tools and forums for asking questions, detailing symptoms, and managing medications.

Online resources include the Caregiver Resource Center, at www.LUNGevity.org/caregiver, which offers emotional support, practical and patient advocacy advice, and other services for caregivers. It is the first online resource wholly devoted to lung cancer caregivers and their very special needs. In 2013, the Foundation added the Survivor Resource Center, which helps to bridge the practical and emotional gaps in lung cancer survivorship while offering a vast network of support for survivors and their loved ones.

Events Across the Country

With over 60 events across the country, LUNGevity has the largest national network of grassroots events aimed at raising money for lifesaving lung cancer research and creating awareness about the disease. Many of these events, including the organization's signature **Breathe Deep** walks and runs, are led by dedicated and passionate local volunteers, bringing together tens of thousands of lung cancer patients, survivors, families, friends, and advocates to change the course of lung cancer. All LUNGevity events offer a place for those impacted by the disease to share, remember, hope, and heal, building a sense of community among those impacted by lung cancer.

Facts About Lung Cancer

- 1 in 16 people in the U.S. will be diagnosed with lung cancer in their lifetime.¹
- 234,030 people will be diagnosed with lung cancer in 2018.¹
- Approximately 60%-65% of all new lung cancer diagnoses are among people who have never smoked or have already quit smoking. About 50% are former smokers and another 10%-15% have never smoked.¹⁻⁶
- Because there is no widely available, effective early diagnostic test for lung cancer, only 16% of people will be diagnosed in the earliest stage, when the disease is most treatable.¹
- Only 19% of all people diagnosed with lung cancer will survive 5 years or more.¹
- Lung cancer kills more people than the next three most common cancers (colorectal, breast, and prostate) combined.¹

- Lung cancer kills almost twice as many women as breast cancer, and almost three times as many men as prostate cancer.¹
- If lung cancer is caught before it spreads, the likelihood of surviving 5 years or more improves to 56%.¹

Sources:

¹Noone AM, Howlader N, Krapcho M, Miller D, Bresi A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

²Burns, DM, Primary prevention, smoking, and smoking cessation: Implications for future trends in lung cancer prevention. *Cancer*, 2000. 89:2506-2509.

³Thun, MJ, et al. Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies. *PLOS Medicine*, 2008. 5(9): e185. Doi:10.1371/journal.pmed.0050185.

⁴Satcher, D, Thompson, TG and Kaplan, JP. Women and smoking: a report of the Surgeon General, *Nicotine Tob Res*, 2002 4(1): 7-20.⁵Park et al. A snapshot of smokers after lung and colorectal cancer diagnosis. *Cancer*, 2012.

<http://onlinelibrary.wiley.com/doi/10.1002/cncr.26545/abstract>

⁶Lung Cancer Facts. Free to Breathe website.

http://www.freetobreathe.org/images/uploads/FreetoBreathe_FactSheet_2017.05.pdf. Updated May 2017. Accessed April 18, 2018.